Literature DB >> 2437245

Human monoclonal antibodies neutralizing human cytomegalovirus.

Y Masuho, Y Matsumoto, T Sugano, S Fujinaga, Y Minamishima.   

Abstract

Hybridomas producing human monoclonal antibodies (MAbs) against human cytomegalovirus (CMV) were generated by fusion of human spleen cells and mouse myeloma cells. Two of the six MAbs obtained neutralized viral infectivity even at concentrations lower than 1 microgram/ml. One MAb required complement for neutralization but the other did not. Both MAbs recognized viral proteins of Mr 130,000 and 55,000. Furthermore, these neutralizing MAbs bound to the surface membrane of CMV-infected cells. These results suggest that human MAbs may provide a new means of passive immunization against CMV infection in humans.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2437245     DOI： 10.1099/0022-1317-68-5-1457

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  10 in total

1.  Evaluation of the AMPLICOR CMV test for direct detection of cytomegalovirus in plasma specimens.

Authors:  M Hiyoshi; S Tagawa; T Takubo; K Tanaka; T Nakao; Y Higeno; K Tamura; M Shimaoka; A Fujii; M Higashihata; Y Yasui; T Kim; A Hiraoka; N Tatsumi
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

2.  Comparative sequence analysis of human cytomegalovirus strains.

Authors:  R Lehner; T Stamminger; M Mach
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

3.  Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus.

Authors:  U Utz; W Britt; L Vugler; M Mach
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

4.  Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.

Authors:  M Ohlin; V A Sundqvist; G Gilljam; U Rudén; F O Gombert; B Wahren; C A Borrebaeck
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

5.  Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne.

Authors:  R R Spaete; A Saxena; P I Scott; G J Song; W S Probert; W J Britt; W Gibson; L Rasmussen; C Pachl
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  Strain-specific neutralization of human cytomegalovirus isolates by human sera.

Authors:  M Klein; K Schoppel; N Amvrossiadis; M Mach
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies.

Authors:  M Ohlin; V A Sundqvist; M Mach; B Wahren; C A Borrebaeck
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  A Luciferase Gene Driven by an Alphaherpesviral Promoter Also Responds to Immediate Early Antigens of the Betaherpesvirus HCMV, Allowing Comparative Analyses of Different Human Herpesviruses in One Reporter Cell Line.

Authors:  Anna Katharina Maier; Raimund Jung; Clarissa Villinger; Axel Schubert; Paul Walther; Christian Sinzger; Diana Lieber
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

10.  Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.

Authors:  Anna Bootz; Astrid Karbach; Johannes Spindler; Barbara Kropff; Nina Reuter; Heinrich Sticht; Thomas H Winkler; William J Britt; Michael Mach
Journal:  PLoS Pathog       Date:  2017-08-30       Impact factor: 6.823
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.